Raloxifene
- Generic Name
- Raloxifene
- Brand Names
- Evista, Optruma, Raloxifene Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C28H27NO4S
- CAS Number
- 84449-90-1
- Unique Ingredient Identifier
- YX9162EO3I
- Background
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation. Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labe...
- Indication
Indicated for the prevention and treatment of osteoporosis in postmenopausal women, as well as prevention and treatment of corticosteroid-induced bone loss.
Indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancer.
- Associated Conditions
- Invasive Breast Cancer, Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment
- Associated Therapies
- -
Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
- Conditions
- Interventions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 82
- Registration Number
- NCT00427700
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2010-01-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 320
- Registration Number
- NCT00383422
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Tuen Mun Hospital
- Target Recruit Count
- 114
- Registration Number
- NCT00371956
- Locations
- 🇨🇳
Tuen Mun Hospital, Hong Kong, China
Raloxifene for Women With Alzheimer's Disease
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 42
- Registration Number
- NCT00368459
- Locations
- 🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸Southern Illinois University School of Medicine, Springfield, Illinois, United States
🇺🇸Kaiser Permanente Santa Rosa, Santa Rosa, California, United States
Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- The Alfred
- Target Recruit Count
- 54
- Registration Number
- NCT00361543
- Locations
- 🇦🇺
Monash Alfred Psychiatry Research Centre, Melbourne, Victoria, Australia
Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen
- Conditions
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2007-05-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 150
- Registration Number
- NCT00332553
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877- CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
- Conditions
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 500
- Registration Number
- NCT00310531
The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-04-23
- Lead Sponsor
- The Alfred
- Target Recruit Count
- 60
- Registration Number
- NCT00206557
- Locations
- 🇦🇺
Alfred Psychiatry Research Centre, Alfred Hospital, Melbourne, Victoria, Australia
Raloxifene Use for The Heart
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10000
- Registration Number
- NCT00190593
- Locations
- 🇺🇸
For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Minneapolis, Minnesota, United States
2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-07-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 810
- Registration Number
- NCT00191425
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Pyrmont, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.